Study on Two Adjuvanted Dose Levels of Panblok H7+MF59 Compared for Immunogenicity and Safety With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older

Clinical trial NCT05608005 · COMPLETED

Trial details

NCT number: NCT05608005
Sponsor: Sanofi Pasteur, a Sanofi Company
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Influenza Healthy Volunteers

Start date: 2022-11-03
Primary completion: 2023-02-18
Enrollment: 581

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.